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Background: In spite of several studies, the impact of homocysteine level and folic acid supplementation on bone
metabolism is yet to be recognized. In this registered clinical trial (IRCT2014042217385N1), we aimed to find out the
power of 6-month folic acid supplementation on homocysteine level and bone metabolism.
Methods: Forty postmenopausal osteoporotic women (50 to 87 years) were enrolled in the study. All participants
were randomized to receive folic acid 1 mg (n = 17) or placebo (n = 14). At baseline, 3 months, and finally 6 months
post intervention, the level of homocysteine, vitamin B12, and bone biomarkers were measured.
Results: Both groups were similar at baseline. The homocysteine decreased in both groups but statistically
non-significant (P > 0.05). The changes of the serum level of vitamin B12, osteocalcin, and β cross laps were
significant between groups after 6 months (P≤ 0.05).
Conclusion: The trend of changes of bone biomarkers after 6 months folic acid supplementation shows that
homocysteine concentration and/or folic acid supplementation have impact on the rate of bone metabolism.
However, further investigations by larger sample size and differentiating age and gender are still needed to clarify
the exact role of folate, homocysteine and vitamin B12.
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Osteoporosis, the senile chronic disease is mainly caused
by estrogen deficiency, while, environmental and lifestyle
factors as well as metabolic and genetic disorders are
contributing. As a chronic senile inflammatory disease, it is
believed that osteoporosis has common pathophysiological
basis with cardiovascular diseases [1]. Hyperhomocysteine-
mia is considered as an independent risk factor for several
chronic senile diseases and conditions including cardiovas-
cular diseases, and Alzheimer disease [2,3]. As the number
of devastating consequences in osteoporotic patients is
increasing worldwide, determining the possible risk fac-
tors and their elimination is crucial. Keeping this in
mind, recent studies have shown the possible role of plate-
lets, inflammation, and homocysteine as well as the role of* Correspondence: poonehsalari@gmail.com
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pathway of cardiovascular diseases and osteoporosis
[4-10]. Accordingly, the role of hyperhomocysteinemia
in the pathogenesis of osteoporosis has been considered
as a focal point. Serum concentration of homocysteine is
inversely related to those of vitamin B12 and folic acid
[11]. From one point during menopause the serum level
of homocysteine is increased and from the other point hy-
perhomocysteinemia is linked with risk of fracture. Folate
supplementation may modify the serum concentration of
homocysteine, and of greater importance may affect frac-
ture risk, because high homocysteine levels increase the
risk of fracture [12]. To our knowledge, there is no enough
data about the effect of folate supplementation and homo-
cysteine lowering therapy on bone metabolism and frac-
ture risk. Our previous systematic review showed the
possible impact of high homocysteine level on bone qual-
ity via induction of osteoclast related bone resorption [3].
With all these in mind, the exact role of homocysteinetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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metabolism is yet to be elucidated. Based on the implica-
tion of bone biomarkers in determination of bone metabol-
ism in osteoporotic patients in a short period of time we
aimed to examine the effect of folic acid supplementation
on serum level of homocysteine and bone metabolism in
postmenopausal osteoporotic women in a randomized,
double-blind, placebo-controlled study. For this purpose,
we selected key indicators such as bone specific alkaline
phosphatase (BALP) from enzymes, osteocalcin (OC) from
bone protein markers, β cross laps (CTX) and pyridinoline
(PYD) from collagenous bone resorption markers to evalu-
ate bone metabolism. All selected bone biomarkers are
easily changed within 3–6 months treatment and usu-
ally used for monitoring effectiveness of treatment.
Furthermore measuring OC and CTX both together is
considered as a reasonable choice for evaluating bone
degradation and synthesis [13].
Methods
Subjects
Forty postmenopausal osteoporotic women who referred
to the Diabetes and Metabolic Disorders Clinic were
enrolled in the double blind randomized clinical trial.
Osteoporosis was diagnosed by the mean of dual energy
X-ray absorptimetry (Hologic®) at femur neck and lumbar
vertebrae in all participants. Osteoporosis was defined on
the basis of WHO criteria as having BMD ≥ 2.5 SD below
the normal mean for young adult women or T-sore ≤ −2.5.
Participants profile including age, age at menopause, habit
of smoking, alcohol consumption, past medical history
and use of medications were collected. Participants with a
history of cancer, acute infection, endocrinology diseases,
taking medications affecting bone metabolism, such as
corticosteroids, gonadotropin releasing hormone (GnRH)
analogues, anticonvulsant drugs, heparin, aluminum con-
taining antacids, thyroid hormones and anti-osteoporosis




Endocrinologic diseases Gonadotropin releasing hormone (GnRH)
and its analogues Antiosteoporotic
medications (bisphosphonates, calcium







Selective serotonin reuptake inhibitors (SSRIs)registered in the Iranian Registry of Clinical Trials with
the code of IRCT2014042217385N1.
The study was approved by the Ethics Committee of
the Endocrinology and Metabolism Research Institute
of Tehran University of Medical Sciences. All partici-
pants signed the written informed consent after receiv-
ing complete information about the study and their
contribution.
Experimental design
All participants were randomly assigned to folic acid or
placebo. The patients’ assignments were double blind. The
method of randomization was simple. Because of few
dose–response studies, the most proper dose of folic acid
to lower homocysteine concentration is not fully clarified.
In a dose–response trial, no significant relation was ob-
served in reduction of homocysteine level when various
doses of folic acid were used [8]. Also, the Homocysteine
Lowering Trialists Collaboration meta-analysis showed no
significant dose-dependent response in the dose range
(800–2000 μg/day) of folic acid [14]. Noteworthy, pharma-
cological doses of folic acid (5 mg/day) may increase the
risk of adverse effects [15]. Therefore, present study was
designed to administer folic acid at dose of 1 mg/day as a
supplement (Figure 1).
Both folic acid and placebo tablets were completely simi-
lar in taste, texture and appearance and were produced by
Rooz Daru Company (Iran). All participants were asked to
inform the clinic in the case of any change in their lifestyle,
medication or occurrence of any side effect. Over the study
period, in each visit, the patients were asked to feel free
to exit from the study if they did not comply with the
described protocol.
Laboratory studies
Blood and urine samples were taken at baseline and after
3 and 6 months. All samples were collected in the early
morning and fasting condition. Blood samples were
centrifuged at 10000 × g for 10 min and kept in the fridge
at −70°C until analysis. Serum levels of bone biomarkers
including OC, BALP, homocysteine, vitamin B12 and
urinary concentrations of PYD and β cross laps were
measured. Serum OC and β cross laps were quantified by
N-MID®Osteocalcin ELISA and Urine BETA CrossLaps®
ELISA Immuno Diagnostic Systems (IDS) (Germany),
respectively. Urinary PYD and serum level of BALP were
measured by MICROVUE PYD EIA® and MICROVUE
BAP EIA® Kits from QUIDEL Corporation (Germany),
respectively. Serum level of homocysteine was quanti-
fied with enzymatic assay by Axis Shield® and serum
level of vitamin B12 was measured by the method of
chemiluminescence By Diasorin Liaison®. Intra- and
inter-assay coefficients of variation (CV) were 2.2%
and 5.1% for osteocalcin, 3.9% and 6.9% for β cross
Figure 1 Consort flowchart.
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and 4.4% and 2.2% for homocysteine.
Statistical analysis
The StatsDirect version 3.0.117 was used for statistical
analysis. Data are expressed as mean ± SD. Normal distri-
bution of data was confirmed by Kolmogorov-Smirnov
test. Baseline values and values after supplementation
were compared using T-test. Comparison between groups
before and after supplementation was performed using
General Linear Model (repeated measure) test. The Pearson
correlation test was used for correlations. P ≤ 0.05 was
considered significant.
Results
The study performed on 40 postmenopausal women, of
those 31 participants completed the study (response
rate = 77.5%). Three participants from the treatment
group and 6 participants from the control group withdrew
the study because of lack of compliance (Figure 1). Table 2
shows the demographic data of all participants. No lifestyle
or medication change as well as side effect was recorded.
The distribution of data was normal. No statistically signifi-
cant difference was found between groups at baseline
(Table 2). The average baseline homocysteine and vitamin
B12 levels were 12.77 μmol/L and 605.72 pg/ml, respect-
ively. The average baseline level of BALP, OC and CTX was
30.5 U/L, 15.48 ng/ml, and 2.74 (μg/mmol Cr), respectivelywhich were in the normal range. The average baseline
urinary PYD level of 43.27 (μg/mmol Cr) was higher than
normal level.
Table 3 presents the biochemical results after supple-
mentation. The serum level of homocysteine decreased
in both groups along the study. No significant change
was found in each group (P = 0.22 in treatment group
versus P = 0.26 in the control group) and between groups
at 6 months (P = 0.06).
In the treatment group, the serum level of vitamin
B12 decreased in the first three months followed by an
increase after 6 months, while in the control group it
decreased during the study period. No significant
change in the serum level of vitamin B12 was found in
each group (P = 0.189 and P = 0.173). After 6 months
serum concentration of vitamin B12 was significantly
lower in the control group compared with the treatment
group (P = 0.01) (Table 3).
The serum level of OC showed a non-significant in-
crease and a decrease in the control group (P = 0.460)
and treatment groups, respectively (P = 0.384). After
6 months, serum level of OC was significantly higher
in the control group compared with the treatment group
(P = 0.034; Table 3).
The serum level of BALP showed a non-significant in-
crease in the treatment (P = 0.614) and control (P = 0.326)
groups. No significant difference was observed between
groups after 6 months (P = 0.543; Table 3).
Table 2 Demographic data and baseline characteristics of study participants
Normal values Treatment group (17) Control group (14) P value
Age (yr) 63.8 ± 8.1 64.2 ± 7.3 0.870
BMI (kg/m2) 25.2 ± 4.5 26.7 ± 3.1 0.290
Age at menopause (yr) 48.8 ± 4.6 46.6 ± 4.7 0.196
Lumbar BMD (g/cm2) 0.67 ± 0.16 0.71 ± 0.06 0.370
Femoral BMD 0.59 ± 0.07 0.60 ± 0.06 0.709
Lumbar T-score −3.11 ± 0.43 −3.01 ± 0.62 0.615
Femoral T-score −2.32 ± 0.63 −2.29 ± 0.46 0.832
Homocysteine (μmol/L) 5-20 11.70 ± 6.63 14.07 ± 3.60 0.242
Vit B12 (Pg/ml) 160-970 745.70 ± 623.07 435.75 ± 245.25 0.091
OC (ng/ml) 12.8-55.0 15.34 ± 6.94 15.66 ± 9.99 0.916
BALP (U/L) 14.2-42.7 29.94 ± 11.02 31.17 ± 11.90 0.767
UPYD (μg/mmol cr) 16.0-37.0 42.99 ± 11.67 43.61 ± 11.14 0.882
U β cross laps (μg/mmol cr) 0.73-7.07 2.45 ± 1.58 3.10 ± 1.75 0.285
All data are presented as Mean ± SD. Yr = year; BMI = body mass index; BMD = bone mineral density; Vit B12 = vitamin B12; OC = osteocalcin; BALP = bone
alkaline phosphatase; UPYD = urine pyridinium cross links; U β cross laps = urine β cross laps.
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significantly increased in both groups, more promin-
ently in the control group (Table 3). After 6 months, the
increase in the level of β cross laps in the control group
was higher than that of treatment group (P = 0.01).
Baseline level of PYD and BALP in the control group
was inversely correlated with BMD and T-score of the
lumbar spine (r = −0.53, P = 0.05) and (r = −0.59, P = 0.02),
respectively. In the control group, the level of β cross
laps at baseline and after 6 months showed a negative
correlation with BMD and T-score of the lumbar spine
(r = −0.61, P = 0.02) and (r = −0.61, P = 0.01), respectively.
In addition homocysteine concentration at the end
of the study was inversely correlated with BMD andTable 3 Statistics for serum concentrations of bone biomarke
Treatment group (N = 17)
Baseline 3 months 6 months
Homocysteine (μmol/L) 11.70 ± 6.63 11.52 ± 4.47 10.17 ± 4.09
CI 95% 8.55-14.85 9.40-13.65 8.23-12.12
Vit B12 (Pg/ml) 745.70 ± 623.07 517.17 ± 260.77 655.17 ± 460.1
CI 95% 449.51-1041.89 393.21-641.14 436.42-873.94
OC (ng/ml) 15.34 ± 6.94 14.10 ± 6.13 13.84 ± 4.87
95% CI 12.03-18.64 11.18-17.02 11.53-16.16
BALP (U/L) 29.94 ± 11.02 30.82 ± 9.66 31.74 ± 9.30
95% CI 24.70-35.19 26.23-35.42 27.33-36.17
UPYD (μg/mmol cr) 42.99 ± 11.67 47.18 ± 9.99 46.61 ± 17.60
95% CI 37.44-48.54 42.43-51.93 38.25-54.99
U β cross laps (μg/mmol cr) 2.45 ± 1.58 2.43 ± 1.22 2.77 ± 1.86
95% CI 1.70-3.20 1.85-3.01 1.90-3.66
All data are presented as Mean ± SD. CI = confidence interval; Vit B12 = vitamin B12
pyridinium cross links; U β cross laps = urine β cross laps.T-score of femur (r =−0.65, P = 0.01) and (r =−61, P = 0.01),
respectively.
Discussion
In this study we aimed to evaluate the effect of folate
supplementation on homocysteine level and bone me-
tabolism in postmenopausal osteoporotic women. In
addition we presumed correlations between homocyst-
eine, bone biomarkers and bone specific characteristics
including BMD and T score. For this purpose we mea-
sured each participant’s BMD and T-score of the femur
and lumbar spine as well as bone biomarkers. In fact
measuring femoral BMD has been considered as the
standard of choice for osteoporosis because this siters in both groups in the study period
P value Control group (N = 14) P value
Baseline 3 months 6 months
0.226 14.07 ± 3.60 14.50 ± 4.78 13.21 ± 4.54 0.266
12.18-15.96 11.99-17.00 10.83-15.59
8 0.189 435.75 ± 245.25 375.50 ± 475.02 235.42 ± 57.96 0.173
307.69-564.23 126.66-624.33 205.70-265.79
0.384 15.66 ± 9.99 16.71 ± 9.92 17.70 ± 10.03 0.460
10.43-20.90 11.51-21.91 12.44-22.96
0.614 31.17 ± 11.90 32.14 ± 14.35 34.46 ± 15.10 0.326
24.94-37.41 24.62-39.66 26.55-42.37
0.369 43.61 ± 11.14 45.11 ± 11.04 51.26 ± 15.56 0.107
37.78-49.45 39.32-50.90 43.11-59.41
0.358 3.10 ± 1.75 3.25 ± 1.92 3.68 ± 2.40 0.398
2.18-4.03 2.24-4.27 2.42-4.94
; OC = osteocalcin; BALP = bone alkaline phosphatase; UPYD = urine
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other sites [16].
Our results showed that supplementation with 1 mg
folic acid non-significantly decreases homocysteine level;
however reduction of homocysteine in the treatment
group was more than control group. According to the
Table 1, the mean homocyteine level of all participants
at baseline was higher than 10 μmol/L which is a mild
elevation [17]. There are several studies which indicate
significant homocysteine lowering effect of folic acid in
doses 400–800 μg per day [18-20]. It is noteworthy to con-
sider that participants of those studies were supplemented
with different doses of vitamin B12 (9–1000 μg/day) in
addition to folic acid. We suppose that lack of significant
effects of folic acid supplementation on homocysteine level
is because of mildly elevated values of homocysteine and
normal levels of vitamin B12 in both groups at the baseline.
Our thought is in agreement with that of Homocysteine
Lowering Trialists Collaboration [14]. In addition to serum
homocysteine level, folate status may be affected. There is a
report that in healthy older adults with normal serum folate
level, folic acid supplementation cannot reduce homocyst-
eine level while in those with low serum folate supplemen-
tation it may lower homocysteine concentration [21]. It
should be noted that in our study and most of other stud-
ies, blood samples were taken in the fasting state while a
study indicated that about 50% of participants show hy-
perhomocysteinemia after methionine load [22]. Therefore
it is suggested that fasting blood sample lacks enough
sensitivity for measuring serum homocysteine. Like-
wise racial differences which affect polymorphism of
the methylenetetrahydrofolate reductase (MTFHR) gene
may affect homocysteine metabolism and should be taken
into account in future studies.
In the control group the hemocysteine level at the end
of the study was negatively correlated with BMD and T
score of femur at baseline (r = −0.65, P = 0.01). Although
several studies indicated significant higher levels of
homocysteine in osteoporotic women and its inverse re-
lationship with BMD of total femur [23-25] or the risk
of fracture [26,27], other investigations did not confirm
the association between homocysteine and BMD and/or
bone markers [28,29]. This is because of a weak correlation
between homocysteine and BMD that failed to be detected
in small sample size. A dose–response relationship between
homocysteine concentration and bone loss in men and
premenopausal women has been reported [30]. In a case–
control study in the Women’s Health Initiative Observa-
tional Study, the modest association of high homocysteine
levels with increased risk of hip fracture was found [12].
On the other hand, a high level of homocysteine or low
level of vitamin B12 and folate were not found as the risk
factors of vertebral fractures in postmenopausal women.
However, the relationship between levels of homocysteineand vitamin B12 and low BMD was recognized [31]. In a
cohort study, association of high homocysteine concentra-
tion and higher bone loss over 4 years in postmenopausal
women was found [32].
Our data showed significant difference in the serum
level of vitamin B12 after 6 months and its serum level
was significantly lower in the control group at the end of
the study (P = 0.01).
Vitamin B12 acts as a cofactor for transformation of
homocysteine to methionine. So both folic acid and vita-
min B12 may reduce serum homocysteine. Vitamin B12
seems to be involved in osteoblast activity and formation
of bone [33], and inhibits osteoclast function [34]; how-
ever, the exact mechanism of vitamin B12 in influencing
bone density is not fully understood.
According to the Framingham Osteoporosis Study, serum
level of vitamin B12 less than 250 pg/ml is considered as
vitamin B12 deficiency and is associated with lower BMD
[35]. The participants in our study had normal serum level
of vitamin B12 and after 6 months its mean interestingly
reached 233.45 pg/ml in the control group.
We found no correlation between vitamin B12 and bone
markers or BMD which is in agreement with other study
which showed no relationship between vitamin B12 supple-
mentation and level of BALP in Mexican women [36].
It was found that vitamin B12 and folate are correlated
with BMD in postmenopausal women and the possibility
of involvement of a mechanistic link was suggested [37].
We observed non-significant increase and decrease in the
level of OC in the control and treatment groups, respect-
ively; however we found a significant difference between
groups. To date no study has evaluated the pattern of alter-
ation of OC in relation to homocysteine.
The level of BALP over the study period showed non-
significant increase in both groups, more profoundly in
the control group.
Homocysteine interacts with lysyl oxidase in collagen
post-translational modifications and cross linking. There-
fore it influences formation of the cross-link [38]. In
addition to bone formation markers, bone resorption
markers including PYD and β cross laps were assessed
in the present study. Our results showed parallel non-
significant increase in the levels of both PYD and β cross
laps in both groups. Furthermore the level of β cross laps
was significantly higher in the control group. According to
the higher level of all measured bone biomarkers in the
control group after 6 months, it is suggested that folic
acid supplementation reduces serum level of homocyst-
eine which follows by suppression of bone metabolism.
However because of small sample size, the power of our
study does not permit to prove our hypothesis. Not only
our study but also studies with longer duration up to
2 years could not show a significant effect of folic acid
supplementation on bone markers [34,39]. Despite a
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acid and vitamin B12 supplementation, no significant
impact of vitamin B supplementation on bone markers
was found in another study while the final level of CTX
and alkaline phosphatase was higher in the control group
[17]. In contrast, a study reported a strong correlation
between homocysteine and serum c-terminal telopeptide
(CTx) levels [40]. The results of a recent longitudinal study
showed a positive correlation between homocysteine and
total alkaline phosphatase. It was concluded that increase
in BALP after hyperhomocysteinemia is the result of induc-
tion of bone regeneration after bone resorption [29]. Those
results may support our results from this point of view.
Regarding the small sample size and enrolment of
patients from one referral center limits extrapolation
of the results of the study. Although we asked the par-
ticipants to follow their routine lifestyle in the study
period, our information about their lifestyle is lacking.
Noteworthy to consider, all of the participants had mildly
elevated serum level of homocysteine which may affect
their response to supplementation; also none of the par-
ticipants were taking calcium and/or vitamin D or other
type of supplement.
Our study presents that level of all of the biochemical
bone markers showed the highest increase in the control
group versus the treatment group in the study period
and the changes in OC, and β cross laps were significant
between groups. Our hypothesis is that serum level of
homocysteine, folate supplementation and serum level
of vitamin B12 may have a preventive effect on bone
metabolism and inversely affect bone metabolism and
its rate, however because of the limited sample size,
the potency of our study is not enough to be extrapo-
lated. Therefore further investigations about the im-
pact of folic acid supplementation on the rate of bone
metabolism in men and women from different ages
with larger sample size is highly recommended.Competing interests
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